We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Monopar Therapeutics Inc (MNPR) USD0.001

Sell:$0.70 Buy:$0.71 Change: $0.0172 (2.56%)
Market closed |  Prices as at close on 21 June 2024 | Switch to live prices |
Change: $0.0172 (2.56%)
Market closed |  Prices as at close on 21 June 2024 | Switch to live prices |
Change: $0.0172 (2.56%)
Market closed |  Prices as at close on 21 June 2024 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Monopar Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for cancer patients. The Company is building a drug candidate pipeline through in-house development as well as the licensing and acquisition of therapeutics in late preclinical and in clinical development stages. The Company has several compounds in development, which include MNPR-101-Zr, MNPR-101-RIT, Camsirubicin and MNPR-202. MNPR-101-Zr is a clinical-stage urokinase plasminogen activator receptor (uPAR)-targeted radio diagnostic imaging agent. MNPR-101-RIT is a late preclinical stage radiotherapeutic for advanced cancers. Camsirubicin is an analog of doxorubicin which has been designed to reduce the cardiotoxic side effects generated by doxorubicin while retaining effective anti-cancer activity. MNPR-202 is an early-stage analog of camsirubicin designed to potentially treat doxorubicin- and camsirubicin-resistant cancers.

Contact details

1000 Skokie Blvd Ste 350
United States
+1 (847) 3880349

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
$14.46 million
Shares in issue:
17.48 million
United States
US dollar

Key personnel

  • Christopher Starr
    Executive Chairman of the Board
  • Chandler Robinson
    Chief Executive Officer, Director
  • Kim Tsuchimoto
    Chief Financial Officer, Treasurer, Company Secretary, Director
  • Karthik Radhakrishnan
    Chief Financial Officer
  • Andrew Cittadine
    Chief Operating Officer
  • Patrice Rioux
    Acting Chief Medical Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.